Clinical Trial Update: Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SPR001 for classic congenital adrenal hyperplasia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 21-hydroxylase Deficiency
• Congenital Adrenal Hyperplasia

Drugs mentioned

• SPR001

Snippet

Sponsor: Spruce Biosciences | Conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia | Phase 2 | Status: COMPLETED | Results posted: 2025-04-01